China Resources Double-Crane Pharmaceutical Co., Ltd.SSE: 600062

(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Mycophenolate Mofetil for Injection of the Wholly-owned Subsidiary Double-Crane Pharmaceutical (Hainan) Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs

· Issued by China Resources Double-Crane Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600062 · · 3 pages · Chinese

Summary by 6ix AI

China Resources Double-Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Double-Crane Pharmaceutical (Hainan) Co., Ltd., has received approval for Mycophenolate Mofetil for Injection after passing the consistency evaluation for generic drugs.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600062china-resources-double-crane-pharmaceutical-co-ltdannouncement-on-mycophenolate-mofetil-for-injection-of-the-wholly-owned-subsidiary-double-crane-pharmaceutical-hainan-co-ltd-passing-the-consistency-evaluation-of-quality-and-efficacy-for-generic-drugs

Release

Announcement on Mycophenolate Mofetil for Injection of the Wholly-owned Subsidiary Double-Crane Pharmaceutical (Hainan) Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from China Resources Double-Crane Pharmaceutical

Later from China Resources Double-Crane Pharmaceutical

All China Resources Double-Crane Pharmaceutical news releases